Akebia Therapeutics
Markets kidney-disease medicines while advancing rare-renal and HIF programs.
$0.8897
After-hours close+0.01 (+1.13%)
At close$0.8798(−6.38%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 37.91%101.70M sharesInsiders 3.00%8.06M sharesOther 59.09%158.51M shares
Shares outstanding 268.26M · Float 262.01M · 97.7% free float
Institutions13F, as of Mar 31, 2026
177 holders · 101.70M shares · 36 new positions · 78 increased · 54 reduced · 33 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 18.69M | 6.97% | −625.2K | May 13, 2026 |
| State Street Corp | 11.61M | 4.33% | −2.07M | May 15, 2026 |
| Vanguard Capital Management LLC | 11.17M | 4.16% | +11.17Mnew | May 15, 2026 |
| Geode Capital Management, LLC | 6.45M | 2.41% | +175.1K | May 15, 2026 |
| Goldman Sachs Group Inc | 3.60M | 1.34% | −1.10M | May 15, 2026 |
| Citigroup Inc | 2.85M | 1.06% | +418.4K | May 11, 2026 |
| Bank of America Corp /DE/ | 2.76M | 1.03% | +506.0K | May 18, 2026 |
| Qube Research & Technologies Ltd | 2.40M | 0.89% | −595.6K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 7.20% | 19.22M | 13G | Jan 21, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| John P. Butler | director, officer: CEO and President | 3.78M | 1.41% | Aug 10, 2026 |
| Steven Keith Burke | officer: SVP, Chief Medical Officer | 948.4K | 0.35% | Feb 4, 2026 |
| Erik Ostrowski | officer: SVP, CFO, CBO & Treasurer | 616.6K | 0.23% | Jul 1, 2026 |
| Carolyn M. Rucci | officer: SVP, Chief Legal Officer | 588.4K | 0.22% | Feb 4, 2026 |
| Nicholas Grund | officer: Chief Commercial Officer | 561.8K | 0.21% | Feb 4, 2026 |
| Richard C. Malabre | officer: SVP, Chief Accounting Officer | 299.4K | 0.11% | Feb 4, 2026 |
| Adrian Adams | director | 236.2K | 0.09% | Jun 22, 2026 |
| Michael W. Rogers | director | 197.4K | 0.07% | Jun 22, 2026 |
| Cynthia Smith | director | 196.6K | 0.07% | Jun 22, 2026 |
| Myles Wolf | director | 169.1K | 0.06% | Jun 22, 2026 |
2 ten-percent owners hold 1.52M shares by Form 4, outside the officers-and-directors figure above · 20 people have not refiled in the last 18 months (6.56M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 29, 2026 | Erik Ostrowskiofficer: SVP, CFO, CBO & Treasurer | Sale | 56,019 | $1.11 | 616,616 |
| Mar 4, 2026 | John P. Butlerdirector, officer: CEO and President | Purchase | 69,270 | $1.25 | 3,367,064 |
| Feb 2, 2026 | John P. Butlerdirector, officer: CEO and President | Sale · 4 lots | 341,305 | $1.39 | 3,206,233 |
| Feb 2, 2026 | Erik Ostrowskiofficer: SVP, CFO, CBO & Treasurer | Sale | 34,951 | $1.39 | 672,635 |
| Feb 2, 2026 | Carolyn M. Rucciofficer: SVP, Chief Legal Officer | Sale · 3 lots | 69,772 | $1.39 | 588,378 |
| Feb 2, 2026 | Steven Keith Burkeofficer: SVP, Chief Medical Officer | Sale · 3 lots | 67,658 | $1.39 | 948,432 |
| Feb 2, 2026 | Nicholas Grundofficer: Chief Commercial Officer | Sale · 2 lots | 84,829 | $1.39 | 561,750 |
| Feb 2, 2026 | Richard C. Malabreofficer: SVP, Chief Accounting Officer | Sale · 2 lots | 49,524 | $1.39 | 299,390 |
CongressHouse and Senate disclosures
Not reported.